SAB Biotherapeutics is trading 5% down now at $3.13, with no company-specific announcement explaining the November 3, 2026 decline found in available search results.
- The company’s latest listed release, dated October 29, says it will report third-quarter results on November 5; the upcoming event does not establish a cause for the decline.
- The provided biotech-sector trend is positive, so it does not explain the stock’s decline.